Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
---|---|
Information provided by: | Boehringer Ingelheim Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00148512 |
The primary objective of this exploratory study is to investigate the efficacy and safety of tesofensine in daily doses (from 0.125 mg to 1.0 mg) in comparison to placebo, over a 14-week treatment period in levodopa treated Parkinson patients with motor fluctuations.
Condition | Intervention | Phase |
---|---|---|
Parkinson Disease |
Drug: 1. Tesofensine (NS 2330) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized Double-Blind Placebo-Controlled Five Parallel-Group Efficacy and Safety Exploratory Study of NS 2330 (0.125mg, 0.25mg, 0.5mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations (Study for Proof of Concept in ADVAnced Pa |
Estimated Enrollment: | 250 |
Study Start Date: | March 2003 |
Estimated Study Completion Date: | February 2005 |
This is a randomized, double-blind, placebo-controlled, five parallel groups efficacy and safety exploratory of tesofensine versus placebo in levodopa treated Parkinson patients with motor fluctuations.
Patients will be treated either with one of the 4 doses of tesofensine (0.125mg, 0.25mg, 0.50 mg or 1.0 mg) or with placebo, once daily, over 14 weeks.
The two co-primary efficacy endpoints are the change in off-time and the change in the Unified Parkinson Disease Rating Scale (UPDRS) II+III total score
Study Hypothesis:
The null hypothesis is that there is no difference between placebo and tesofensine.
The alternative hypothesis is that treatment with tesofensine is superior to treatment with placebo.
Comparison(s):
For the primary comparison between tesofensine and placebo, change in percentage off-time during waking hours will be based on reports from patient's diary (completed at day -3 and day-2 prior to the study visits) and change in the UPDRS II+III will be based on UPDRS II averaged for on and off periods and UPDRS III evaluated at on periods during the study visits.
Ages Eligible for Study: | 42 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Main inclusion criteria:
Main exclusion criteria:
Study Chair: | Boehringer Ingelheim Study Coordinator | BI France S.A.S. |
Study ID Numbers: | 1198.101 |
Study First Received: | September 7, 2005 |
Last Updated: | January 12, 2007 |
ClinicalTrials.gov Identifier: | NCT00148512 |
Health Authority: | France: AFSSAPS; Austria: BMGF; Germany: BfArM; Spain: AEMPS; United Kingdom: Medicines and Healthcare Products Regulatory Agency; Netherlands: MEB |
Levodopa Ganglion Cysts Movement Disorders Parkinson Disease Basal Ganglia Diseases |
Central Nervous System Diseases Parkinsonian Disorders Neurodegenerative Diseases Brain Diseases |
Nervous System Diseases |